Condition: Cytomegalovirus (CMV) · Sponsor: Takeda
Cytomegalovirus (CMV) is a common virus that infects many people. It can cause serious illness in people with weak immune systems especially in those undergoing transplants. Maribavir is a medicine approved for treating CMV infection in adults after transplant. The main aim of this study is to check the use of maribavir and learn how safe and effective in treating adults with CMV infection after transplant in Belgium in line with the Belgian reimbursement criteria. During the study, a participant's data will be collected for 2 years. The study does not have fixed visits to the hospital, but it is recommended collect data from routine visits and contacts.
This description comes directly from the study's public registry record.
Takeda Contact · +1-877-825-3327 · medinfoUS@takeda.com
Always discuss trial participation with your own doctor first.
| Hôpital Erasme | Anderlecht, Belgium | Recruiting |
| Institut Jules Bordet | Anderlecht, Belgium | Recruiting |
| Cliniques Universitaires Saint-Luc | Brussels, Belgium | Recruiting |
| UZA | Edegem, Belgium | Recruiting |
| UZGent | Ghent, Belgium | Recruiting |
| UZBrussel | Jette, Belgium | Recruiting |
| UZLeuven | Leuven, Belgium | Recruiting |
| CHU de Liège - site Sart Tilman | Liège, Belgium | Recruiting |
| CHU UCL Namur - site Godinne | Yvoir, Belgium | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06677892